Meeting
2021 ASCO Annual Meeting
Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).
Authors
Evangelos Terpos
National and Kapodistrian University of Athens School of Medicine, Athens, Greece
Evangelos Terpos , Ashraf Badros , Rakesh Popat , Paula Rodríguez-Otero , Asim Farooq , Bennie Jeng , Simona Degli Esposti , Eric Lewis , Ira Gupta , Joanna Opalinska , Antonio Palumbo , Suzanne Trudel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03525678
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8033)
DOI
10.1200/JCO.2021.39.15_suppl.8033
Abstract #
8033
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.
First Author: Malin Hultcrantz
Poster
2020 ASCO Virtual Scientific Program
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
First Author: Sagar Lonial
Poster
2016 ASCO Annual Meeting
Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
First Author: Philippe Moreau
Poster
2024 ASCO Annual Meeting
Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
First Author: Allison Graeter